Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
Li Wang(Jiangsu University), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Elizabeth R. Plimack(Fox Chase Cancer Center), Sumanta K. Pal(City of Hope), Bruce S. Fischer(Bristol-Myers Squibb (United States)), Nina Bhardwaj(Mount Sinai Hospital), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Jun Zhu(China National Nuclear Corporation), David J. Mulholland(Icahn School of Medicine at Mount Sinai), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Adam M. Farkas(Icahn School of Medicine at Mount Sinai), Abdel Saci(Harvard University), Andrea Necchi(Vita-Salute San Raffaele University), Amir Horowitz(Cancer Institute (WIA)), Péter M. Szabó(Bristol-Myers Squibb (United States)), John P. Sfakianos(Mount Sinai Medical Center), Yixuan Gong(Memorial Sloan Kettering Cancer Center), Alberto Martini(The University of Texas MD Anderson Cancer Center)
Cited by 144
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k